高血压患者如何服用依普利酮？

Is a new type of selective aldosterone receptor antagonist, eplerenone can be used alone or in combination with other antihypertensive drugs for the treatment of hypertension. Eplerenone from India's Lupine Pharmaceuticals is the most purchased product by patients. How do patients with high blood pressure take India's Lupine Pharmaceuticals eplerenone?

Eplerenone from India's Lupine Pharmaceuticals can be used alone or in combination with other antihypertensive drugs. The recommended initial dose for use alone is 50mg/time, once/day. Obvious antihypertensive effects appear within four weeks of taking the drug. If the antihypertensive effect is not obvious, it can be increased to 50mg/time, 2 times/day. Higher dosages are not recommended, otherwise there is an increased risk of adverse reactions such as hyperkalemia.

Clinical trials evaluate the clinical efficacy and safety of eplerenone and losartan in the treatment of essential hypertension. Methods 80 patients were selected and randomly divided into eplerenone group and losartan group, 40 cases in each group. Eplerenone tablets 50 mg and Losartan potassium tablets 50 mg were administered orally once/d for 12 weeks. Results Compared with before treatment, the blood pressure of the two groups dropped significantly, and the differences were statistically significant (P0.05); comparing the two groups, there was no statistically significant difference in the blood pressure reduction between eplerenone and losartan (P=0.05). Comparing the biochemical indicators between the two groups, the difference was not statistically significant (P0.05).

The conclusion shows that it is a good medicine for treating high blood pressure. It has a protective effect on the liver, heart and kidneys without damaging the organs. This medicine can promote urination without losing potassium. Eplerenone and losartan. 1 time/d. Taking 50 mg can effectively control blood pressure in patients with mild and moderate hypertension. Good safety and compliance.

Recommended related hot articles: /newsDetail/86621.html